Company Information

  

Address: NO. 588 SHIJI XI AVENUE  
City: XIANYANG, SHAANXI PROVINCE 
State:  
Zip Code: 712046 
Telephone: 011-86-29-33686638 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

Biostar Pharmaceuticals, Inc. ("Biostar") is a holding company that, through our wholly-owned subsidiary Shaanxi Biostar Biotech, Ltd. ("Shaanxi Biostar") and our variable interest entities ("VIEs") Shaanxi Aoxing Pharmaceutical Co., Ltd. ("Aoxing Pharmaceutical"), and Shaanxi Weinan Huaren Pharmaceuticals Ltd. ("Shaanxi Weinan") develops, manufactures and markets pharmaceutical products for a variety of diseases and conditions in the People's Republic of China (the "PRC" or "China"). Corporate Organization and History Biostar was incorporated in the State of Maryland on March 27, 2007. Through the steps described immediately below, we became the indirect holding company for Aoxing Pharmaceutical, a medical and pharmaceutical developer, manufacturer and marketer in the PRC on November 1, 2007. On June 15, 2007, we formed Shaanxi Biostar in the PRC as our wholly-owned subsidiary. Because Shaanxi Biostar is wholly-owned by Biostar, a U.S.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
03/2017-2.60NAN/E
12/2016-2.50NAN/E
09/2016-14.29NAN/E
06/2016-14.14NAN/E
03/2016-11.25NAN/E
12/2015-79.80NAN/E
09/20152.94NA1.66

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.18Total Liab/Total Assets0.13
Net Inc/Total Assets-0.13Total Liab/Inv Cap0.16
Net Inc/Inv Cap-0.16Total Liab/Comm Equity0.18
Pretax Inc/Net Sales-1.28Interest Coverage Ratio-13.77
Net Inc/Net Sales-2.39Curr Debt/Equity0.06
Cash Flow/Net Sales2.06LTD/EquityNA
SG&A/NetSales1.51Total Debt/Equity0.06
Asset Utilization   Liquidity  
Net Receivables Turnover0.21Quick Ratio1.28
Inventory Turnover7.32Current Ratio1.31
Inventory Day Sales0.02Net Rec/Curr Assets0.95
Net Sales/Work Cap1.37Inv/Curr Assets0.02
Net Sales/PP&E0.41  

Income Statement (Millions)

  3/31/2017 12/31/2016 9/30/2016 6/30/2016
Total Revenues(Net Sales) 0.00 0.32 0.64 0.62
Cost of Goods Sold 0.00 0.35 0.34 0.32
Selling & Admin Exps 1.04 0.98 0.78 0.83
Operating Income -1.04 5.93 -1.96 -6.86
Interest Exp 0.05 0.06 0.11 0.00
Pretax Income -1.01 6.04 -1.56 -6.84
Other Income 0.07 0.18 0.50 0.02
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -1.01 3.39 -1.56 -6.90

Balance Sheet (Millions)

Assets 3/31/2017 12/31/2016 9/30/2016 6/30/2016
Cash & Short Term Investments 0.48 0.17 0.66 0.21
Receivables - Total 5.69 7.03 6.19 7.83
Inventories - Total 0.16 0.17 0.44 0.32
Total Current Assets 6.34 7.37 7.29 8.35
Net Property, Plant & Equipment 5.82 5.87 6.27 6.41
Total Assets 41.49 42.50 40.56 42.06
Liabilities        
Accounts Payable 2.53 2.84 4.10 3.85
Debt in Current Liabilities 2.34 2.33 2.42 2.43
Total Current Liabilities 5.31 5.62 6.53 6.29
Long-Term Debt NA NA NA NA
Total Liabilities 5.31 5.62 6.53 6.29
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock NA NA NA NA
Common Stock 0.00 0.00 0.00 0.00
Retained Earnings -3.56 -2.54 -5.93 -4.37
Treasury Stock NA NA NA NA
Total Stockholders' Equity 36.18 36.88 34.03 35.76
Total Liabilities and Stockholders' Equity 41.49 42.50 40.56 42.06

Cash Flow Summary (Millions)

Categories 3/31/2017 12/31/2016 9/30/2016 6/30/2016
Net Cash Provided by Operating Activities 0.32 4.00 0.56 0.01
Net Cash Provided by Investing Activities 0.00 -6.38 0.00 0.00
Net Cash Provided by Financing Activities 0.00 1.69 0.00 -0.00

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/201249.32-20.00--
12/201352.730.81--
12/201461.424.85--
12/201527.13-25.11-79.80
12/20162.38-5.70-2.50
Growth Rates-53.11----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/178100.40




Report Date : 10/16/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.